Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | 3 | — | — | 5 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 3 | 3 | — | — | 5 |
Drug common name | Rivoglitazone |
INN | rivoglitazone |
Description | Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.
|
Classification | Small molecule |
Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1 |
PDB | — |
CAS-ID | 185428-18-6 |
RxCUI | — |
ChEMBL ID | CHEMBL2104753 |
ChEBI ID | — |
PubChem CID | 3055168 |
DrugBank | — |
UNII ID | 3A3N0634Q6 (ChemIDplus, GSRS) |